NCT07021989 2026-03-17ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin LymphomaUniversity of California, San FranciscoPhase 2 Not yet recruiting38 enrolled
NCT03618550 2025-12-02Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin LymphomaMemorial Sloan Kettering Cancer CenterPhase 2 Recruiting257 enrolled